This story has been updated with additional comments from Elaine Mardis during the plenary clinical trials session of the AACR annual meeting. The headline has also been updated.
NEW YORK − BioNTech's personalized cancer vaccine RO7198457 combined with the PD-L1 inhibitor atezolizumab (Genentech's Tecentriq) appears to be active and well tolerated in patients with solid tumors, according to new data presented at the second virtual session of the American Association for Cancer Research's annual meeting last Friday.